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 Human mesenchymal stem cells (hMSCs) possess the capacity for multi-lineage 
differentiation. Under the appropriate conditions, hMSCs can undergo cell fate 
decision to commit to adipogenic, osteogenic, chondrogenic, or myogenic lineages. 
In this regard, the adipogenesis of human adipose tissue-derived mesenchymal 
stem cells (hAT-MSCs) can be used as a model for phenotype-based screening of 
anti-aging skin compounds with lipofilling effects.  
 The kojyl cinnamate derivative, Seletinoid G, has been clinically proven to have 
anti-aging effects in human skin. However, the efficacy in the phenotype assay was 
not sufficient to perform molecular target identification research. In this study, we 
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developed novel kojyl cinnamate derivatives for improved adiponectin promoting 
activity in hAT-MSCs. Through target deconvolution, we found that the 
adiponectin-secreting activities of kojyl cinnamates were correlated with PPARγ 
and PPARα, but not PPARδ activation. In a further investigation, we found that 
kojyl cinnamates with high binding affinities towards PPARγ and PPARα 
significantly increased the expressions of cholesterol and fatty acid synthesizing 
enzymes in both hAT-MSCs and primary normal human keratinocytes (NHKs). 
Our findings suggest that kojyl cinnamate derivatives with PPARγ and PPARα dual 
agonism have the potential to repair altered skin barrier function and improve aged-
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 The phenotype-based approach to drug discovery can be used as an alternative to 
the conventional target-based method, and has the ultimate advantage of being able 
to evaluate candidate molecules at a more biologically and disease relevant context. 
However, the phenotypic method requires follow-up studies to elucidate the direct 
molecular targets responsible for the observed responses (1-2). Human 
mesenchymal stem cells (hMSCs) can be used to develop phenotype-based assays 
for various pathophysiological conditions. In particular, the adipogenesis of human 
adipose tissue-derived mesenchymal stem cells (hAT-MSCs) can be used as a 
model system to screen for active compounds that may improve age-related 
decrease of subcutaneous adipose tissue (3).  
 With increasing age, the adipose tissue undergoes significant changes in both 
composition and abundance. The age-dependent decline in adipogenesis and the 
subsequent regression of adipocyte lipid metabolism contribute to the progressive 
thinning and wrinkling of the skin (4-5). Adipogenesis involves a network of 
transcription factors that consists of peroxisome proliferator-activated receptor 
(PPAR) and CCAAT/enhancer binding proteins (C/EBPs), which collectively 
enhances the expressions of adipocyte specific genes (6-7). Adiponectin, which is 
expressed exclusively in adipose tissue, is an adipokine known to exhibit anti-
inflammatory, pro-apoptotic, and insulin sensitizing properties (8-10). However, it 
is also involved in repairing altered connective tissue that results as of both 
intrinsic and extrinsic skin aging. For instance, adiponectin can improve age-
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associated breakdown of extracellular matrix components, such as type 1 collagen 
and elastin (11-12). Adiponectin can be also up-regulated in response to 
pharmacological agents that modulate PPAR, PPAR, and PPAR activity, and 
examples include pioglitazone and rosiglitazone (13). Furthermore, its expression 
can be regulated by cyclin-dependent kinase 5 (CDK5), which phosphorylates the 
nuclear receptor PPARγ at serine 273 (14). In this regard, molecules with 
adiponectin-promoting activities during adipogenic differentiation can be 
investigated to determine whether they can interact with PPARs or CDK5. 
 In a previous study, we reported that the kojyl cinnamate ester derivative, 2-((3E)-
4(2H,3H-benzo[3,4-d]1,3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-
pyran-4-one (Seletinoid G), repaired collagen and extracellular matrix (ECM) 
breakdown in aged skin by increasing the expressions of type 1 procollagen, 
tropoelastin, and fibrillin-2, while inhibiting the expression of interstitial 
metalloproteinases (MMPs), such as MMP-1 (15). We also found that Seletinoid G 
significantly promoted adiponectin production during adipogenesis in hAT-MSCs 
(16). However, the direct molecular targets responsible for the Seletinoid G-
induced up-regulation of adiponectin production were not clearly identified due to 
its relatively weak potency on PPARs or CDKs (16). In this study, we synthesized 
novel kojyl cinnamate ester derivatives with more potent adiponectin-producing 
and -secreting activities to elucidate the molecular targets involved in the 
adipogenic differentiation of hAT-MSCs. Target deconvolution of the newly 
synthesized kojyl cinnamate ester derivatives demonstrated that the adiponectin-
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producing and -secreting activities were associated with dual agonism on the 
nuclear receptors PPAR and PPAR.  
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Ⅱ. Materials and Methods 
 
1. Cell culture and differentiation  
hAT-MSCs were purchased from Lonza, Inc. (Walkersville, MD) and maintained 
according to the manufacturer’s instructions. hAT-MSCs were cultured in Dulbecco 
Modified Eagle’s Medium (DMEM) containing low glucose (1 g/L) and 
supplemented with 10% fetal bovine serum (FBS), antibiotics, and Glutamax TM  
(Invitrogen, Carlsbad, CA). To promote adipocyte differentiation, the growth 
medium was replaced with DMEM containing high glucose (4.5 g/L) and 
supplemented with 10% FBS, 10 g/mL insulin, 0.5 M dexamethasone, and 0.5 mM 
3-isobutyl-1-methylxanthine (IBMX) (IDX condition). Dexamethasone, insulin, 
IBMX, glibenclamide, troglitazone, Wy-14643, and aspirin were purchased from 
Sigma–Aldrich (St. Louis, MO, USA). hAT-MSCs were grown in the IDX 
condition and treated twice with either glibenclamide, troglitazone, Wy-14643, or 
compounds 1 to 12 for a total of 7 days. 
Primary normal human keratinocytes (NHKs) from neonatal foreskin were 
purchased from Lonza (Basel, Switzerland) and cultured in KBM medium with 
KGM2 growth supplements consisting of insulin, human epidermal growth factor, 
bovine pituitary extract, hydrocortisone, epinephrine, transferrin, and 
gentamicin/amphotericin B (Sigma, St Louis, MO, USA). NHKs were treated with 
troglitazone, Wy-14643, or compounds 1 to 12 for a total of 24 h. 
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2. Oil Red O and Hematoxylin staining  
The level of adipocyte differentiation was assessed using Oil Red O stain from 
Sigma–Aldrich (St. Louis, MO, USA) as an indicator of intracellular lipid 
accumulation. Differentiated adipocytes were rinsed twice with phosphate-buffered 
saline (PBS), fixed with 10% formalin in PBS (pH 7.4) for 1 h, and then washed 
once with 60% isopropanol. Cultures were stained with 0.2% Oil Red O reagent for 
10 min at room temperature and washed four times with H2O. To visualize the 
nucleus, the differentiated hBM-MSCs were counterstained with hematoxylin 
reagent from Sigma–Aldrich (St. Louis, MO, USA) for 1 min and then washed four 
times with H2O. The level of adipocyte differentiated was observed using an 
inverted phase-microscope. 
3. Enzyme-linked immunosorbent assay (ELISA)  
 The R&D Systems QuantikineTM immunoassay kit (Minneapolis, MN, USA) 
was used for quantitative measurement of adiponectin in cell culture supernatants. 
Cytokine concentrations were determined according to the manufacturer’s 
instructions 
4. Nuclear receptor (NR) assays 
 LanthascreenTM’s time resolved fluorescence resonance energy transfer (TR-
FRET) competitive binding assay kits (Invitogen, Carlsbad, California, United 
States) were used to evaluate the PPAR, PPARδ, and PPAR binding activities of 
chemical ligands. All assay measurements were performed according to the 
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manufacturer’s instructions using CLARIOstar (BMG LABTECH, Ortenberg, 
Germany).  
4. Total RNA isolation and quantitative real-time PCR (Q-
RT-PCR) 
 Total RNA samples were isolated using Trizol’s reagent (Invitogen, Carlsbad, CA, 
United States), followed by a purification step using the Qiagen RNeasy kit 
(Qiagen, Valencia, CA, United States). The concentration of RNA in each sample 
was determined spectrophotometrically at 260 nm. The integrity of each RNA 
sample was evaluated using Agilent 2100 BioAnalyzer (Agilent Technologies, 
Santa Clara, CA, USA). Total RNA from each sample was reversed transcribed to 
cDNA using the Superscript Reverse Transcriptase (RT) II Kit (Invitogen, Carlsbad, 
CA, United States). TaqMan Universal Master Mix II and Q-RT-PCR primer sets 
(Applied Biosystems, Foster City, CA, USA) were used to analyze cDNA samples 
for 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1, Hs00940429_m1), 3-
hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2, Hs00985427_m1), 3-
hydroxy-3-methylglutaryl-COA reductase (HMGCR, Hs00168352_m1), Fatty acid 
synthase (FASN, Hs01005622_m1), Fatty acid desaturase 1 (FADS1, 
Hs01096546_m1), Acetyl-CoA carboxylase beta (ACACB, Hs01565914_m1), 
Fatty acid desaturase 2 (FADS2, Hs00927433_m1), Fatty acid binding protein 4 
(FABP4, Hs01086177_m1), Adiponectin (ADIPOQ, Hs00605917_m1), and 
Acetyl-CoA acetyltransferase 2 (ACAT2, Hs00255067_m1). Human 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 4333764F) was used to 
 14 
normalize sample variations. Q-RT-PCR was performed with an Applied 
Biosystems 7500 Real-Time PCR System (Applied Biosystems). Relative gene 
expression levels were quantified using equations from a mathematical model 
developed by Pfaffl. 
6. Statistical analysis 
 Experimental values are expressed as the mean ± standard deviation. Statistical 
analysis was performed using one-way ANOVA. P-values of less than 0.05 and 




1. Target identification of Seletinoid G. 
Seletinoid G is a synthetic retinoid with an α, β-unsaturated ketone group that was 
designed based on the structures of kojic acid and cinnamic acid. It was assumed 
that the γ-pyranone ring of the skin lightening-agent, kojic acid, would mimic the 
carboxylic acid moiety of the compound, retinoid acid, which exerts anti-aging 
activity in human skin (15). Furthermore, Seletinoid G was also designed with a 
cinnamate moiety based on the fact that the constituents of Cinnamomum cassia 
extracts can promote adipogenesis in hAT-MSCs (16). In our previous study, we 
found that the kojyl cinnamate derivative, Seletinoid G, can repair altered dermal 
connective tissue in aged and photoaged skin (15). In a follow up study, we found 
that Seletinoid G significantly increased adiponectin production at 30µM and 
60µM in hAT-MSCs during adipogenesis (Figure 2A). Additionally, relative to the 
IDX control, we noticed that Seletinoid G increased both the number and size of 
lipid droplets in differentiated adipocytes (Figure 2B). However, the efficacy of 
Seletinoid G was too low to perform molecular target identification studies. When 
we evaluated the nuclear receptor binding activities of Seletinoid G to the PPAR 
isotypes, we found that it competitively displaced the selective ligands for PPARγ, 
PPARα, and PPARδ by less than 50% (Figure 1C). With this respect, we 
synthesized additional kojyl cinnamate derivatives for improved phenotypic 








Figure 1. Chemical structures of retinoic acid, kojic acid, cinnamic acid, and 
Seletinoid G  
Chemical structures of all-trans retinoic acid (A), kojic acid (B), cinnamic acid (C), 
and Seletinoid G (D) were drawn using ChemBioDraw Ultra
®
 (Perkinelmer, 







Figure 2. Adiponectin promoting activity of Seletinoid G is independent of 
PPAR activation 
hAT-MSCs were grown under IDX conditions and/or co-treated with Seletinoid G 
at increasing concentrations. On the 7th day of culture, the cell supernatant was 
harvested and used to evaluate the levels of adiponectin secreted (A). Values 
represent mean adiponectin level ± SD (n = 3). * p ≤ 0.05 and ** p ≤ 0.01. Oil red 
O staining was performed to determine the amount of lipid droplets accumulated 
over the 7 days of culturing in relation to the IDX control (B). DMEM was used as 
a negative control to indicate the absence of adipogenesis. Glibenclamide (10µM) 
was used as a positive control. TR-FRET NR competitive binding assays were 
performed to determine the binding activities of Seletinoid G to PPARγ, PPARα, 
and PPAR (C).  
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2. Kojyl cinnamate derivatives promote adiponectin-secreting 
activity in hAT-MSCs during adipogenesis.  
To determine whether the newly synthesized kojyl cinnamate derivatives promote 
adipogenesis in hAT-MSCs, compounds 2-12 were added to IDX supplemented 
medium and tested for adipogenic potential. As shown in Figure 3A, the addition of 
compounds 2, 5, 7, and 8 to the IDX condition promoted adiponectin production in 
hAT-MSCs by 221%, 244%, 282%, 275%, respectively. In comparison to 
Seletinoid G, compounds 2, 5, 7, and 8 exhibited potent adiponectin-promoting 
activities at both 30µM and 60µM (Figure 3B). In a follow-up study to examine a 
dose-dependence response, all four of the compounds showed maximal adiponectin 
production at non-cytotoxic concentrations of 60µM (Figure 4A). To further 
demonstrate the extent of adipogenesis in hAT-MSCs treated with kojyl cinnamate 
derivatives, Oil Red O and hematoxylin staining was used to assess the level of 
intracellular lipid accumulation. As anticipated, in comparison to the IDX control, 
compounds 2, 5, 7, and 8 increased both the number and size of lipid droplets 







Figure 3. Evaluation of the adiponectin-promoting activity of kojyl cinnamate 
derivatives during adipogenesis in hAT-MSCs  
The effects of kojyl cinnamate derivatives on the adiponectin-producing activities 
in hAT-MSCs during adipogenesis were evaluated using ELISA. hAT-MSCs grown 
under IDX supplemented medium and co-treated with compounds 2-12. The levels 
of adiponectin in the cell culture supernatants were harvested 7 days after the initial 
treatment (A, B). Glibenclamide (10µM) was used as a positive control. Values 






Figure 4. Kojyl cinnamate derivatives promote adiponectin production in a 
concentration-dependent manner  
Concentration-dependent effects of kojyl cinnamate derivatives on adiponectin 
production during adipogenesis in hAT-MSCs. hAT-MSCs were treated with 
increasing concentrations of kojyl cinnamates in IDX supplemented medium. The 
cell culture supernatants were harvested on the 7
th
 day in culture and used to 
measure the amount of adiponectin secreted. Troglitazone, Wy-14643, and Aspirin 
were used as positive controls (A). Values represent mean  SD (n=3). The levels 
of lipid accumulation of differentiated hAT-MSCs were qualitatively measured 
using Oil Red O staining. The extent of lipid accumulation was assessed relative to 
IDX control (B). The adiponectin levels of compounds 2, 5, 7, and 8 at 30µM and 
60µM were determined relative to the IDX control (C).   
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3. Target deconvolution of kojyl cinnamate derivatives 
 PPARs are involved in the process of adipocyte differentiation (17-19). 
Therefore, we speculated that the adiponectin-promoting potential of kojyl 
cinnamate derivatives in hAT-MSCs could be due to the activation of the PPAR 
signaling pathway. In this study, we evaluated the PPAR binding activities of kojyl 
cinnamates using TR-FRET NR competitive binding assays. Of the kojyl 
cinnamates, compounds 5 and 7 exhibited the highest binding affinities towards 
PPARγ, with overall binding activities of 84.6% and 76.8%, respectively (Figure 
5A). Similarly, compounds 5 and 7 had the highest binding affinities towards 
PPARα, and competitively displaced the fluorescently labeled PPARα ligand by 
73.0% and 59.6%, respectively (Figure 5B). In a further study, we found that there 
were significant correlations between the adipogenic potentials and the PPARγ and 
PPARα binding activities of kojyl cinnamates. The correlation coefficient (r
2
) at 30 
M was 0.74 (p < 0.003) and 0.39 (p < 0.03) for PPARγ and PPARα respectively 
(Figure 6A, 6B). However, there was no significant correlation observed between 
the adiponectin-promoting activities and PPAR binding affinities of the newly 
synthesized kojyl cinnamates. The value of the correlation coefficient (r
2
) at 30M 
was determined to be 0.02 (p < 0.68) (Figure 6C). Next, we examined the dose–
response relationship of the binding activities of compounds 5 and 7 to PPAR and 
PPAR subtypes. As anticipated, the kojyl cinnamate derivatives 5 and 7 displayed 
significant competitive binding activities in a concentration-dependent manner (Fig. 
7A, 7B). The Ki values of compounds 5 and 7 were 6.7 and 7.0 for PPAR and 8.0 
and 9.5 for PPAR, respectively (Table 1, 2). Consistent with the literature, the 
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agonists Troglitazone and Wy-14643 bound specifically to PPAR and PPAR, 
respectively (Figure 7A, 7B). The competitive and selective activation of PPARγ 
and PPARα suggests that the binding activities of the two PPAR isotypes are 
positively correlated with the adipogenic potential of kojyl cinnamate esters during 






Figure 5. Nuclear binding activities of Seletinoid G and its related kojyl 
cinnamate derivatives  
PPAR binding affinities of Seletinoid G and its kojyl cinnamate derivatives. TR-
FRET competitive binding assays of compounds 1-12 were performed at 30M as 
ligands of (A) PPARγ, (B) PPARα, and (C) PPAR. The positive controls (P) were 
GW1929 for PPARγ, GW7647 for PPARα, and GW0742 for PPAR. N stands for 
negative control. Values from the present study are expressed as mean ± standard 





Figure 6. Correlation between adiponectin levels and PPAR binding affinities 
of Seletinoid G and its kojyl cinnamate derivatives 
The correlation coefficients between the adiponectin levels and PPAR (A), 
PPAR (B), and PPAR (C) binding affinities at 30 μM of kojyl cinnamates were 
calculated using Pearson’s correlation coefficients (r
2
). Values represent mean ± SD 





Figure 7. PPAR and PPAR binding activity of kojyl cinnamate derivatives   
In order to determine the dose-dependent binding affinities of compounds 5 and 7 
to PPARγ (A) and PPARα (B) nuclear receptors, TR-FRET competitive binding 
assays were performed. The inhibition constant (Ki) was calculated by applying the 
Cheng-Prusoff equation. The positive controls included Troglitazone for PPAR 
and Wy-14643 for PPAR. DMSO in buffer was used as a blank control. Values 
were expressed in terms of percentage compared to each positive control. 
Percentage values represent mean ± SD (n = 3).  
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4. Kojyl cinnamate derivatives modulate cholesterol and free 
fatty acid synthesis in aged skin models 
 Next, to investigate the role of PPAR activation on skin homeostasis, we analyzed 
the mRNA levels of key enzymes involved lipid metabolism. Ligands of PPAR 
and PPAR are important modulators of lipogenesis and help promote adipogenic 
differentiation (17, 20). Although there have been a lot of studies based on PPAR 
mono-agonists in cutaneous biology, the role of PPAR/ dual agonists in human 
skin models still remain to be identified. Aged skin is characterized by an overall 
decrease in lipid synthesis and is particularly associated with a profound decrease 
in cholesterol production (21). To investigate whether PPAR and PPAR dual 
activation can reverse altered cholesterol metabolism in aged skin, we evaluated 
the effects of kojyl cinnamate derivatives on the mRNA levels of the cholesterol 
metabolizing enzymes, 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
(HMGCR), 3-hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMGCS1), and 
acetyl-coenzyme A acetyl transferase 2 (ACAT2) in differentiated hAT-MSCs. In 
this study, we found that compounds 5 and 7 significantly increased the mRNA 
levels of HMGCR and HMGCS1 at 24h (p < 0.01) (Figure 9A-9C). We also 
noticed the mRNA expressions of fatty acid desaturase 1 and 2 (FADS1, FADS2), 
fatty acid synthase (FASN), acetyl CoA carboxylase B (ACACB) were markedly 
up-regulated by compounds 5 and 7 after 24h (p < 0.05) (Figure 10-11). Our results 
suggest that the kojyl cinnamate derivatives 5 and 7 have the potential to increase 
cholesterol and fatty acid biosynthesis in human subcutaneous adipose tissue. Next, 
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to confirm that the activation of PPARγ and PPARα by kojyl cinnamate derivatives 
promotes adipogenesis in hAT-MSCs, the mRNA levels of ADIPOQ and FABP4 
were quantified. In this study, the expression of the PPAR downstream target genes, 
ADIPOQ and FABP4, were measured as markers of adipogenesis. As anticipated, 
the PPARγ agonist, Troglitazone, increased the transcription of adipogenic genes 
associated with mature adipocyte phenotype. In contrast, despite its lipid 
accumulating effect, the PPARα agonist, Wy-14643, had no significant effect on 
the mRNA levels of ADIPOQ and FABP4 in hAT-MSCs. However, the combined 
treatment of the two mono-agonists synergistically up-regulated the transcription of 
genes involved in adipocyte differentiation. Similarly, compounds 5 and 7, which 
exhibit PPARγ and PPARα dual agonism, increased both ADIPOQ and FABP4 
gene transcription (p < 0.05, p < 0.01) (Figure 12A, 12B). 
Aged skin displays an overall reduction in epidermal lipid synthesis, which results 
in abnormal barrier function (21). In order to investigate whether kojyl cinnamate 
derivatives can improve decreased skin barrier capacity, we quantified the mRNA 
levels of enzymes involved in cholesterol and free fatty acid metabolism. Similarly 
to the results observed in hAT-MSCs, compounds 5 and 7 significantly increased 
HMGCS1 and ACAT2 expressions in primary normal human keratinocytes (NHKs) 
at 24h (p < 0.05) (Figure 13A, 13D). Although the kojyl cinnamate derivatives 5 
and 7 increased HMGCR mRNA expression, it was not statistically significant 
(Figure 13C). Interestingly, we found that only the PPARα agonist, Wy-14643, 
significantly up-regulated HMGCS2 expression (p < 0.01) (Figure 13B). In this 
present study, we also found that compounds 5 and 7 significantly up-regulated the 
expressions of FADS1, FADS2, and FABP4 in NHKs after 24h (p < 0.05) (Figure 
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14). Our results suggest that PPARγ and PPARα dual agonists, such as compounds 
5 and 7, have the potential to repair epidermal barrier abnormality by increasing the 




Figure 8. Role of PPARs in cutaneous biology 
The known functions of PPAR and PPAR in skin homeostasis. PPAR  and  
isotypes modulate lipogenesis in both human epidermal and subcutaneous tissues. 
The effects of PPAR/ dual agonists on human aged skin models remain to be 





Figure 9. Kojyl cinnamate derivatives modulate cholesterol synthesis in 
differentiated hAT-MSCs 
Differentiated hAT-MSCs were treated with Wy-14643, Troglitazone, compound 5 
or compound 7. 24h after treatment, total RNA was extracted and Q-RT-PCR was 
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performed for HMGCS1, HMGCR, and ACAT2 (A-C). GAPDH was used as an 
internal control for Q-RT-PCR standardization. The positive controls included Wy-
14643 for PPAR, Troglitazone for PPAR, and the co-treatment of Wy-14643 and 
Troglitazone for PPAR/. Values from the present study are expressed as means ± 








Figure 10. The effects of PPAR/  dual agonists on lipogenesis in 
differentiated hAT-MSCs  
The effects of kojyl cinnamate esters on the expression of genes associated with 
lipogenesis in differentiated hAT-MSCs. 24h after compound treatment, total RNA 
was extracted and Q-RT-PCR was performed for FADS1 and FADS2 (A, B). 
GAPDH was used as an internal control for Q-RT-PCR standardization. The 
positive controls for PPAR and PPAR were Wy-14643 and Troglitazone, 
respectively. Wy-14643 and Troglitazone co-treatment was used as a positive 
control for PPAR/. Values from the present study are expressed as means ± SD 







Figure 11. Kojyl cinnamate derivatives regulate fatty acid synthesis in 
differentiated hAT-MSC  
IDX-induced differentiated hAT-MSCs were treated with Wy-14643, Troglitazone, 
or compounds 5 and 7. 24h in culture, total RNA was extracted and Q-RT-PCR was 
performed for FASN (A) and ACACB (B). GAPDH was used as an internal control 
for Q-RT-PCR standardization. Results are the mean ± SD (n = 3). * p <0.05 and 







Figure 12. Transcriptional expression profile of ADIPOQ and FABP4 in 
differentiated hAT-MSCs 
IDX-induced differentiated hAT-MSCs were treated with Wy-14643, Troglitazone, 
or compounds 5 and 7. 24h in culture, total RNA was extracted and Q-RT-PCR was 
performed for ADIPOQ (A) and FABP4 (B). GAPDH was used as an internal 
control for Q-RT-PCR standardization. Results are the mean ± SD (n = 3). * p 





Figure 13. Kojyl cinnamate derivatives 5 and 7 modulate mevalonate pathway 
regulation in NHKs 
NHKs were treated with Wy-14643, Troglitazone, and compound 5 or 7 in KGM 
medium. 24h after treatment, total RNA was extracted and Q-RT-PCR was 
performed for HMGCS1, HMGCS2, HMGCR, and ACAT2 (A-D). GAPDH was 
used as an internal control for Q-RT-PCR standardization. Values from the present 





Figure 14. Transcriptional expression profile of free fatty acid metabolism 
associated genes in NHKs  
NHKs were treated with Wy-14643, Troglitazone, compound 5 or compound 7. At 
24h in cell culture, total RNA was extracted and Q-RT-PCR was performed for 
FADS1, FADS2, and FABP4 (A-C). GAPDH was used as an internal control for Q-
RT-PCR standardization. Values from the present study are expressed as means ± 




Figure 15. Schematic representation of the function of PPAR/ dual agonists 
on the metabolic pathways leading to the synthesis of cholesterol and fatty 
acids in skin 
PPAR/ dual agonists, such as kojyl cinnamate esters 5 and 7, promote cholesterol 
and free fatty acid synthesis in the human skin by increasing the expression of 
lipogenic enzymes, such as HMG-CoA synthase, HMG-CoA reductase, acetyl-CoA 
carboxylase, and fatty acid synthase. PPAR and PPAR dual activators can act as 






The aim of this study was to investigate the mechanism by which kojyl cinnamate 
derivatives exert anti-aging potential in human skin. In our prior study, we found 
that the kojyl cinnamate derivative, Seletinoid G, promoted ECM synthesis and 
adiponectin production in cell-based assays (16-17). When we performed a target 
identification study to evaluate whether Seletinoid G transactivated nuclear 
receptors involved in the regulation of adipogenesis, we found that there were no 
significant activities detected (17). In order to elucidate the molecular targets 
involved in the adiponectin-promoting activity of kojyl cinnamate derivatives in 
hAT-MSCs, we synthesized additional compounds with kojyl cinnamate 
pharmacores for improved efficacy in phenotype-based assays. In this study, we 
demonstrated that the compounds 5 and 7 promote adiponectin production in IDX-
induced differentiated adipocytes. Subcutaneous adipose tissue-derived adiponectin 
can stimulate the production of major ECM components in the dermis and can 
reduce age-related decrease of skin elasticity and volume (9, 22-23). Previous 
studies have also demonstrated that adiponectin from subcutaneous adipocytes can 
decrease collagen breakdown by inhibiting MMP activity, and conversely enhance 
procollagen synthesis by dermal fibroblasts (11, 22-23). Moreover, adiponectin can 
also regulate multiple activities in the skin by mediating endocrine, paracrine or 
autocrine mechanisms (24-27). Adiponectin secreted from subcutaneous adipose 
tissues may act in a paracrine manner to regulate anti-aging mechanisms in the 
dermal and epidermal tissues of the skin. With this respect, it can be suggested that 
 44 
compounds 5 and 7 may have the ability to indirectly increase ECM production in 
human skin. 
 In this study, we hypothesized that the PPAR signaling pathway may be 
involved in the adiponectin-secreting activity of kojyl cinnamate derivatives in 
hAT-MSCs during adipogenesis. PPARs are ligand-activated transcription factors 
that belong to the family of nuclear receptors, and consist of three isotypes (,, 
and ), which are expressed in the human skin (28-29). These nuclear receptors 
have multiple roles in skin homeostasis, and equally participate in the formation of 
the skin barrier (29-31). Moreover, the cross-talk between the PPAR isotypes and 
their transcriptional network are known to be involved in the modulation of 
adipocyte differentiation (7, 17, 32). Although kojyl cinnamate esters have been 
shown to promote adiponectin production in hAT-MSCs during adipogenic 
differentiation, the pharmacological mechanisms behind their phenotypic changes 
are not fully understood (17). In the present study, we demonstrated that the 
activation of PPAR and PPAR by kojyl cinnamate esters is positively correlated 
with the levels of secreted adiponectin. Furthermore, we revealed that the 
adiponectin-promoting activity of kojyl cinnamates does not involve the activation 
of PPAR. Previous studies have demonstrated that PPAR activators, such as 
fibrates, can induce the expression of adiponectin and its associated receptors in 
adipose tissues (33-35). It has also been reported that PPAR can act as a master 
regulator of adipocyte differentiation, and that its activation by selective ligands, 
such as thiazolidinediones (TZDs), can up-regulate the expression and secretion of 
adiponectin (36-38). Consistent with these reports, our findings demonstrate that 
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PPAR and PPAR dual-agonists, such as compounds 5 and 7, are important 
modulators of adipocyte differentiation, and that their activation stimulates both the 
expression and secretion of adiponectin in subcutaneous adipose tissue.  
More importantly, we also demonstrated that PPAR and PPAR activation 
increases lipogenesis in differentiated adipocytes. Phenotypic evaluation using Oil 
Red O staining revealed that the kojyl cinnamate esters, 5 and 7, enhance both the 
number and size of lipid droplets in hAT-MSCs. In a further study, we found that 
PPAR activation up-regulate the transcription of enzymes involved in cholesterol 
and fatty acid synthesis. Aged skin is characterized by the reduced ability of 
subcutaneous adipocytes to produce and accumulate essential lipids, and the 
inability to maintain adequate levels of lipids may contribute to the overall 
weakening and thinning of the skin (39-42). PPAR activation by selective 
agonists, such as Wy-14643, can reverse age-related decrease of lipid synthesis, 
and knocking-out its expression in the skin can cause structural and functional 
abnormalities that delays barrier recovery (20, 43). According to past studies, 
PPAR agonists can increase mRNA expressions of key enzymes involved in 
cholesterol, fatty acid, and ceramide synthesis (44-46). Consistent with these 
findings, we found that Wy-14643-induced PPAR activation increases mRNA 
levels of mevalonate pathway associated genes, such as HMGCS1, HMGCR, and 
ACAT2. However, we noticed that there was a synergistic effect on lipid synthesis 
when both PPAR and PPAR were simultaneously activated. Relative to the 
PPAR and PPAR treatments alone, the co-treatment of the agonists Wy-14643 
and Troglitazone enhanced the expressions of cholesterol synthesizing enzymes. 
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Similarly, we found that the PPAR/ dual agonists, 5 and 7, stimulate 
cholesterogenesis in hAT-MSCs. Cholesterol plays an important role in dermal 
ECM remodeling, and is known to mediate collagen degradation by MMPs. Low 
levels of cholesterol are associated with an increase in MMP-9 expression, and 
inducing cholesterol synthesis can abrogate ERK-JNK pathway dependent 
activation of AP-1 transcription factor, which is involved in the inhibition of 
procollagen synthesis (47-51). Overall, these findings suggest that PPAR/ dual 
agonists, such as compounds 5 and 7, may exhibit anti-aging potential in the skin 
by indirectly promoting ECM synthesis.  
Likewise, to determine whether PPAR and PPAR dual activation enhances the 
activities of key regulators involved in fatty acid biosynthesis, we evaluated the 
mRNA levels of FASN and ACACB. Our findings indicate that relative to the 
PPAR and PPAR activations alone, the activation of the two PPAR isotypes 
promotes fatty acid synthesis in hAT-MSCs. The subcutaneous adipose tissue of 
chronologically and photo-aged skin is characterized by a marked decrease in fatty 
acid levels, and this can be reversed by stimulating the expression of lipid 
synthesizing enzymes (52-53). Additionally, it has been suggested that fatty acid 
desaturase (FADS) deficiency in aged skin may be associated with abnormal skin 
lipid composition, and may result in pathological conditions like atopic dermatitis 
and psoriasis (53-54). In this present study, we evaluated whether kojyl cinnamate 
derivatives with PPAR and PPAR agonism can up-regulate the activity of FADS, 
which are involved in modulating cutaneous lipogenesis. Our findings 
demonstrated that compounds 5 and 7 significantly increase FADS1 and FADS2 
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expression in differentiated hAT-MSCs. FADS are expressed in multiple tissues, 
including the skin, and are known to decrease in activity over age (54-55). Based 
on clinical studies of adipose tissue fatty acid composition, it has been indicated 
that reduced levels of FADS are associated with abnormal barrier function that 
results as of decreased levels of essential long-chain fatty acid derivatives in the 
permeability barrier (56-58). These findings demonstrate that compounds 5 and 7 
may exhibit anti-aging potential in the skin by promoting FADS activity, which 
decreases over age. Taken together, our results suggest that PPAR and PPAR 
dual activation by kojyl cinnamate esters can improve age-dependent decline of 
adipogenesis and lipogenesis in subcutaneous adipose tissue. 
Aside from their roles in hAT-MSCs, PPARs are known to be involved in both 
the differentiation and formation of the epidermal barrier (59-63). According to 
past studies, it has been demonstrated that PPAR and PPAR activators accelerate 
barrier recovery in skin constructs following acute barrier abrogation by 
stimulating epidermal lipid synthesis and lamellar body formation (20, 64-66). 
Impaired barrier function is heavily associated with the decreased incidence of 
epidermal lipid synthesis, and enhancing the rates of cholesterol, fatty acid and 
ceramide synthesis to maintain lipid ratios of 3:1:1, respectively, can accelerate 
barrier recovery (66-69). Chronologically and photo-aged skin displays an overall 
reduction in lipid content, and is particularly associated with a profound decrease 
in cholesterol levels (67, 70-75). Although there has been a lot of focus based on 
the effects of PPAR and PPAR mono-activators on the stimulation of human 
epidermal lipogenesis, there have been very few reports based on the roles of 
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PPAR/ co-agonists. Here, we demonstrated that PPAR and PPAR dual 
activation by kojyl cinnamate derivatives 5 and 7 can increase the activities of rate-
limiting enzymes involved in the synthesis of cholesterol in NHKs. Topical 
application of PPAR, PPAR, and PPAR selective activators, such as Wy-14643, 
GW1514, and ciglitazone, has been demonstrated to increase lipogenesis in both 
human and murine models of aged or barrier disrupted skin (20, 33, 46, 52). 
Consistent with these findings, we demonstrated that the PPAR isotypes  and  
have the potential to improve altered barrier function in human skin by enhancing 
epidermal lipid synthesis. However, we found that relative to the Wy-14643 and 
Troglitazone treatments alone, the PPAR/ dual agonists, 5 and 7, synergistically 
enhanced cholesterol synthesizing enzymes, such as HMGCS1, HMGCR, and 
ACAT2. Moreoever, similar to the observations made in differentiated hAT-MSCs, 
we found that the kojyl cinnamate derivatives increased the expression of enzymes 
involved in the formation and regulation of essential fatty acids. All together, these 
findings suggest that the dual activation of PPAR and PPAR by kojyl cinnamate 
esters can normalize altered epidermal cholesterol and fatty acid synthesis in aged 
skin models. However, the effects of kojyl cinnamate derivatives on ceramide 
synthesis remain to be elucidated. Further studies should focus on the underlying 
mechanisms behind PPAR and PPAR activation in the epidermal lipid synthesis 
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아디포넥틴 분비촉진 효과를 
나타내는 코질신나메이트 유도체들의 
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노화에 따라 피부는 표피의 지질대사 기능의 저하로 피부장벽 기능이 
약화되고, 피하지방층이 감소하여 주름 등의 표현형이 나타난다. 피부 
항노화 물질을 발굴하기 위한 표현형 기반의 효능평가모델은 분자타겟 
기반의 평가법에 비해 노화의 생리학적 조건과 유사한 환경에서 
후보물질을 발굴하고 작용기전을 연구할 수 있다는 장점이 있다. 사람의 
중간엽줄기세포는 지방세포, 골형성세포, 연골세포 등 다양한 세포로 
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분화하는 특징이 있어 항노화 물질 연구 및 다양한 질환의 신약 
후보물질 탐색에 대표적인 세포표현형 모델로 활용된다. 본 연구에서는 
사람의 지방조직유래 중간엽줄기세포의 지방분화 과정에 아디포넥틴 
분비를 촉진하는 코질신나메이트(kojyl cinnamate) 유도체의 
생리활성과 작용기전을 평가하였다. 코질신나메이트 유도체 중, 
셀레티노이드 G 는 인체의 임상 실험에서 피부항노화 효과가 검증된 바 
있지만, 분자약물학적 수준에서 항노화 작용기전은 불명확하다. 새로운 
코질신나메이트 유도체들 중 사람의 중간엽줄기세포의 지방분화 
과정에서 셀레티노이드 G 보다 아디포넥틴 분비촉진효과가 우수한 것을 
확인하였다. 아디포넥틴 분비 촉진 효과가 우수한 코질신나메이트 
유도체를 활용하여 분자약물학적 타겟을 규명하기 위해 지방조직의 분화 
및 기능에 중요한 세포핵수용체인 퍼옥시솜 증식체-활성화 
수용체(peroxisome proliferator-activated receptor, PPAR)에 대한 
결합반응 실험을 수행하였다. 코질신나메이트 유도체들이 PPARγ 와 
PPARα 에 결합하였지만, PPARδ 에는 결합하지 않음을 확인하였다. 
코질신나메이트 유도체들의 아디포넥틴 분비촉진 효과는 PPARγ 와 
PPARα 결합력과 상관성이 있음을 확인하였다. PPARγ 와 PPARα 에 
강한 결합력을 보이는 코질신나메이트 유도체는 지방조직유래 
중간엽줄기세포와 각질형성세포의 콜레스테롤 대사에 중요한 
HMGCR 과 HMGCS1 을 유의미하게 증가시켰다. 결론적으로 
코질신나메이트 유도체들은 PPARγ 와 PPARα 이중효능제로서 사람의 
중간엽줄기세포의 아디포넥틴 분비를 촉진하고, 각질형성세포의 
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콜레스테롤 생합성 조절 효소의 발현을 증가시킴으로서 피부 항노화 
효과를 나타낸다. 
주요어 : 표현형 기반 평가, 사람의 지방조직유래 중간엽줄기세포, 
지방분화, 아디포넥틴, 퍼옥시솜 증식체-활성화 수용체  
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